ValuEngine lowered shares of Metlife (NYSE:MET) from a hold rating to a sell rating in a research note released on Thursday morning, ValuEngine reports.
Several other analysts have also recently issued reports on the stock. Barclays upped their price objective on shares of Metlife from $52.00 to $55.00 and gave the company an overweight rating in a research note on Wednesday, May 22nd. Deutsche Bank upped their price objective on shares of Metlife from $46.00 to $47.00 and gave the company a hold rating in a research note on Friday, April 12th. Citigroup set a $42.00 price objective on shares of Metlife and gave the company a sell rating in a research note on Thursday, May 23rd. UBS Group upped their price objective on shares of Metlife from $45.00 to $48.00 and gave the company a neutral rating in a research note on Tuesday, April 9th. Finally, Wells Fargo & Co upped their price objective on shares of Metlife from $55.00 to $57.00 and gave the company an outperform rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $50.91.
Shares of MET traded down $1.04 during mid-day trading on Thursday, hitting $47.29. 9,084,518 shares of the company were exchanged, compared to its average volume of 3,504,183. Metlife has a 1-year low of $37.76 and a 1-year high of $51.16. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 0.24. The firm’s 50 day simple moving average is $49.75. The stock has a market cap of $46.97 billion, a PE ratio of 8.77, a price-to-earnings-growth ratio of 1.07 and a beta of 1.09.
Metlife (NYSE:MET) last released its quarterly earnings results on Wednesday, July 31st. The financial services provider reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.07. Metlife had a net margin of 9.28% and a return on equity of 10.17%. The firm had revenue of $16.45 billion during the quarter, compared to the consensus estimate of $16.43 billion. During the same quarter in the prior year, the firm earned $1.30 EPS. The company’s revenue for the quarter was down 22.4% on a year-over-year basis. On average, equities research analysts expect that Metlife will post 5.6 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 6th will be paid a dividend of $0.44 per share. The ex-dividend date is Monday, August 5th. This represents a $1.76 annualized dividend and a yield of 3.72%. Metlife’s dividend payout ratio is presently 32.65%.
Institutional investors have recently bought and sold shares of the company. Jackson Grant Investment Advisers Inc. grew its stake in shares of Metlife by 4,407.7% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 586 shares of the financial services provider’s stock valued at $25,000 after buying an additional 573 shares during the period. Kavar Capital Partners LLC purchased a new stake in shares of Metlife in the 2nd quarter valued at approximately $25,000. Osborn Williams & Donohoe LLC purchased a new stake in shares of Metlife in the 1st quarter valued at approximately $26,000. Meridian Wealth Management LLC purchased a new stake in shares of Metlife in the 1st quarter valued at approximately $26,000. Finally, Advisory Alpha LLC purchased a new stake in shares of Metlife in the 1st quarter valued at approximately $27,000. 75.75% of the stock is owned by institutional investors and hedge funds.
Metlife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Featured Story: Convertible Shares
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.